JP2013166765A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013166765A5 JP2013166765A5 JP2013080823A JP2013080823A JP2013166765A5 JP 2013166765 A5 JP2013166765 A5 JP 2013166765A5 JP 2013080823 A JP2013080823 A JP 2013080823A JP 2013080823 A JP2013080823 A JP 2013080823A JP 2013166765 A5 JP2013166765 A5 JP 2013166765A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- natalizumab
- subject
- medicament according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55812004P | 2004-04-01 | 2004-04-01 | |
| US60/558,120 | 2004-04-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506536A Division JP2007531761A (ja) | 2004-04-01 | 2005-03-30 | ステロイド節約剤およびそれを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013166765A JP2013166765A (ja) | 2013-08-29 |
| JP2013166765A5 true JP2013166765A5 (https=) | 2015-03-19 |
Family
ID=34972924
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506536A Pending JP2007531761A (ja) | 2004-04-01 | 2005-03-30 | ステロイド節約剤およびそれを使用する方法 |
| JP2013080823A Pending JP2013166765A (ja) | 2004-04-01 | 2013-04-08 | ステロイド節約剤およびそれを使用する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506536A Pending JP2007531761A (ja) | 2004-04-01 | 2005-03-30 | ステロイド節約剤およびそれを使用する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20050260193A1 (https=) |
| EP (1) | EP1734997B1 (https=) |
| JP (2) | JP2007531761A (https=) |
| AU (1) | AU2005232571A1 (https=) |
| CA (1) | CA2561364C (https=) |
| DK (1) | DK1734997T3 (https=) |
| ES (1) | ES2554754T3 (https=) |
| HU (1) | HUE026236T2 (https=) |
| IL (1) | IL178302A (https=) |
| MY (1) | MY162179A (https=) |
| NO (1) | NO20064979L (https=) |
| NZ (1) | NZ594476A (https=) |
| PL (1) | PL1734997T3 (https=) |
| PT (1) | PT1734997E (https=) |
| SI (1) | SI1734997T1 (https=) |
| TW (1) | TWI462744B (https=) |
| WO (1) | WO2005099776A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2358763C2 (ru) | 2003-02-10 | 2009-06-20 | Элан Фармасьютикалз, Инк. | Композиции иммуноглобулина и способ их получения |
| MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| AU2012202575B2 (en) * | 2004-11-19 | 2014-11-20 | Biogen Ma Inc. | Treatment for Multiple Sclerosis |
| CN103169965A (zh) * | 2004-11-19 | 2013-06-26 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
| AU2006348180A1 (en) * | 2006-09-13 | 2008-03-20 | Warner Chilcott Company, Llc | Methods of treatment for ulcerative colitis |
| JP2008120722A (ja) * | 2006-11-10 | 2008-05-29 | Benesis Corp | 生物由来製品の偽薬 |
| WO2008125903A2 (en) * | 2006-12-12 | 2008-10-23 | Chaim Sheba Medical Center | Method of inhibiting an undesired immune response |
| US8682440B2 (en) | 2009-08-03 | 2014-03-25 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
| US8721620B2 (en) | 2009-12-24 | 2014-05-13 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
| EP2543388A4 (en) * | 2010-03-04 | 2013-11-27 | Dainippon Sumitomo Pharma Co | MEDICINAL PRODUCT FOR INFLAMMATORY ENDURANCE |
| SMT202000306T1 (it) | 2010-04-16 | 2020-07-08 | Biogen Ma Inc | Anticorpi anti-vla-4 |
| US20130209476A1 (en) * | 2010-06-04 | 2013-08-15 | The Brigham And Women's Hospital Inc. | Treatment of inflammatory disorders |
| HUE050713T2 (hu) | 2010-10-25 | 2020-12-28 | Biogen Ma Inc | Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával |
| US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| DK3311834T3 (da) | 2011-05-02 | 2026-04-20 | Millennium Pharmaceuticals Inc | Formulering til anti-alfa4beta7-antistof |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| ES2667854T3 (es) * | 2011-07-07 | 2018-05-14 | Holy Stone Healthcare Co., Ltd. | Composición para uso en el tratamiento y la prevención de trastornos relacionados con la inflamación |
| WO2013078375A2 (en) * | 2011-11-23 | 2013-05-30 | Amgen Inc. | Administration of alpha4beta7 hetero-dimer-specific antibody |
| WO2016100301A1 (en) | 2014-12-15 | 2016-06-23 | The Brigham And Women's Hospital, Inc. | Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders |
| US10738121B2 (en) | 2015-02-27 | 2020-08-11 | The General Hospital Corporation | Therapeutic use of integrin-binding antibodies |
| US12037398B2 (en) | 2018-06-04 | 2024-07-16 | Biogen Ma Inc. | Anti-VLA-4 antibodies having reduced effector function |
| CN112997256A (zh) * | 2018-06-14 | 2021-06-18 | 阿斯利康(英国)有限公司 | 使用皮质类固醇医药组合物治疗和预防哮喘症状的方法 |
| US20230181714A1 (en) * | 2020-05-27 | 2023-06-15 | Vanderbilt University | Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| US5224539A (en) | 1991-06-14 | 1993-07-06 | Coen Company, Inc. | Cooling system for air heaters and the like |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| AU2505599A (en) * | 1998-02-10 | 1999-08-30 | Cangene Corporation | Method for the prevention and treatment of a type i hypersensitivity disorder |
| DE60140748D1 (de) * | 2000-06-30 | 2010-01-21 | Dainippon Sumitomo Pharma Co | Thiazol-derivate zur verwendung als entzündungshemmende mittel |
| US6794506B2 (en) * | 2000-07-21 | 2004-09-21 | Elan Pharmaceuticals, Inc. | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 |
| EP1372720A4 (en) * | 2001-03-02 | 2006-07-26 | Medimmune Inc | PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3 |
| JP2005512946A (ja) * | 2001-05-09 | 2005-05-12 | ノバルティス アクチエンゲゼルシャフト | 選択的免疫調節法 |
| US20030008844A1 (en) * | 2001-05-17 | 2003-01-09 | Keryx Biopharmaceuticals, Inc. | Use of sulodexide for the treatment of inflammatory bowel disease |
| AU2002346999B2 (en) * | 2001-10-19 | 2007-11-08 | Centre Hospitalier Regional Et Universitaire De Tours | Methods and compositions to evaluate antibody treatment response |
| US6878518B2 (en) * | 2002-01-22 | 2005-04-12 | The Trustees Of The University Of Pennsylvania | Methods for determining steroid responsiveness |
| PL215263B1 (pl) * | 2002-02-25 | 2013-11-29 | Elan Pharm Inc | Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku |
| CA2514125A1 (en) | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
-
2005
- 2005-03-29 MY MYPI20051380A patent/MY162179A/en unknown
- 2005-03-30 SI SI200532025T patent/SI1734997T1/sl unknown
- 2005-03-30 EP EP05768245.2A patent/EP1734997B1/en not_active Revoked
- 2005-03-30 AU AU2005232571A patent/AU2005232571A1/en not_active Abandoned
- 2005-03-30 PT PT57682452T patent/PT1734997E/pt unknown
- 2005-03-30 WO PCT/US2005/010848 patent/WO2005099776A2/en not_active Ceased
- 2005-03-30 PL PL05768245T patent/PL1734997T3/pl unknown
- 2005-03-30 DK DK05768245.2T patent/DK1734997T3/en active
- 2005-03-30 CA CA2561364A patent/CA2561364C/en not_active Expired - Lifetime
- 2005-03-30 NZ NZ594476A patent/NZ594476A/xx not_active IP Right Cessation
- 2005-03-30 JP JP2007506536A patent/JP2007531761A/ja active Pending
- 2005-03-30 ES ES05768245.2T patent/ES2554754T3/es not_active Expired - Lifetime
- 2005-03-30 HU HUE05768245A patent/HUE026236T2/en unknown
- 2005-03-31 TW TW094110385A patent/TWI462744B/zh not_active IP Right Cessation
- 2005-04-01 US US11/096,074 patent/US20050260193A1/en not_active Abandoned
-
2006
- 2006-09-26 IL IL178302A patent/IL178302A/en active IP Right Grant
- 2006-10-31 NO NO20064979A patent/NO20064979L/no not_active Application Discontinuation
-
2013
- 2013-04-08 JP JP2013080823A patent/JP2013166765A/ja active Pending
-
2014
- 2014-07-28 US US14/444,862 patent/US20150056205A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013166765A5 (https=) | ||
| JP6654967B2 (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| RU2770050C2 (ru) | Способ лечения с применением традипитанта | |
| Ding et al. | Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single‐center, single‐arm, open‐label study | |
| Keystone et al. | Adalimumab therapy in rheumatoid arthritis | |
| JP7564347B2 (ja) | 多発性硬化症を治療するためのｌｏｕ０６４ | |
| Santomasso | Anticancer drugs and the nervous system | |
| Shukla et al. | Novel non-biologic targets for inflammatory bowel disease | |
| JP2025514978A (ja) | 脊髄性筋萎縮症を治療するためのミオスタチン阻害薬の使用 | |
| KR20120050512A (ko) | 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료 | |
| Seni et al. | Advancements in ulcerative colitis management: a critical assessment of etrasimod therapy | |
| Lolis et al. | Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies | |
| US20240270842A1 (en) | Use of an anti-cd19 antibody to treat myasthenia gravis | |
| CN106659738B (zh) | 阿尔茨海默病(ad)的治疗和预防 | |
| AU2022230300A1 (en) | Treatment and/or reduction of occurrence of migraine | |
| CANSEVER et al. | Successful Rapid Desensitization of Two Teenagers with Rituximab Hypersensitivity. | |
| Cianci et al. | Subcutaneous immunoglobulin in infantile chronic inflammatory demyelinating polyneuropathy: a case report | |
| Nobile-Orazio et al. | Chronic inflammatory demyelinating polyradiculoneuropathy and related disorders | |
| Boucher et al. | Emerging Drugs for Amyotrophic Lateral Sclerosis | |
| AU2024210360A1 (en) | Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy | |
| Sorbera et al. | hu1124 | |
| Fasanmade et al. | T1132 Pharmacokinetics and Exposure-Response Relationship of Ustekinumab, a Human Monoclonal Antibody to Interleukin 12/23, in Patients with Moderate-to-Severe Crohn's Disease | |
| Hanauer et al. | T1130 Efficacy of Delayed-Release Oral Mesalamine in Patients Who Received Previous Ulcerative Colitis Treatment | |
| KR20260042531A (ko) | Pcsk9 억제제를 이용하여 콜레스테롤 관련 질환을 치료 또는 예방하기 위한 방법 | |
| EA052907B1 (ru) | Применение антитела к cd19 для лечения миастении гравис |